We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current GNMSF market cap is 15.77B. The company's latest EPS is DKK 119.4065 and P/E is 2.01.
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Revenue | 10.11B | 8.48B | 14.6B | 16.47B | 21.53B |
| Operating Income | 6.31B | 3.02B | 6.36B | 5.32B | 6.7B |
| Net Income | 4.76B | 3.01B | 5.52B | 4.35B | 7.84B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Total Assets | 21.14B | 24.63B | 30.28B | 35.29B | 45.81B |
| Total Liabilities | 2.02B | 2.43B | 2.84B | 3.68B | 9.11B |
| Total Equity | 19.12B | 22.2B | 27.44B | 31.61B | 36.7B |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | DKK (kr) | |
| Operating | 6.43B | 2.23B | 3.91B | 7.38B | 7.77B |
| Investing | -2.35B | -961M | -2.76B | -1.28B | -9.91B |
| Financing | 71M | -420M | -789M | -606M | -3.92B |
| Market Cap | 15.77B |
| Price to Earnings Ratio | 2.01 |
| Price to Sales Ratio | 0.73 |
| Price to Cash Ratio | 1.6 |
| Price to Book Ratio | 0.43 |
| Dividend Yield | - |
| Shares Outstanding | 65.69M |
| Average Volume (1 week) | 284 |
| Average Volume (1 Month) | 559 |
| 52 Week Change | -18.37% |
| 52 Week High | 323.018 |
| 52 Week Low | 186.61 |
| Spread (Intraday) | 49.58 (18.71%) |
| Company Name | Genmab A S (PK) |
| Address |
kalvebod brygge 43 copenhagen 1260 |
| Website | https://www.genmab.com |
| Industry | biogenetic (human) (H4) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
